# International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi

> **NCT03072030** · PHASE4 · COMPLETED · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 2000 (actual)

## Conditions studied

- Ebola Virus Disease
- Prevention

## Interventions

- **BIOLOGICAL:** GamEvac-Combi (vaccine)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT03072030
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-03
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-07-31
- **Target enrollment:** 2000 (ACTUAL)
- **Last updated:** 2020-08-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03072030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03072030, "International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03072030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*